



NETWORK Notification

Notice Date: February 11, 2025
To: Indiana Medicaid Providers
From: CareSource
Subject: Newborn RSV Prevention

Summary

CareSource would like to remind providers the medications available to prevent severe respiratory syncytial virus (RSV) during the newborn period. RSV continues to be one of the top reasons newborns are hospitalized every year.

Impact

Abrysvo is the only vaccine approved for pregnant people during weeks 32-36 of pregnancy. Beyfortus (Nirsevimab) is an antibody that can be given one time during RSV season in newborns up to 8 months of age. Synagis (Palivizumab) is another antibody given multiple times during RSV season to infants more susceptible to severe RSV infections. If a person receives Abrysvo during 32-36 weeks of pregnancy, the newborn will not need the antibody.

Members may receive the medication during an office visit, in the hospital or at a pharmacy.

Requirements for RSV Products:

Indiana Medicaid	Medical Prior Authorization Required	Pharmacy Prior Authorization Required
Abrysvo	No	No; Age limit for VFC redirection (≥ 19 no PA), unless pharmacy is VFC provider
Beyfortus (Nirsevimab)	No	Not Covered
Synagis	Yes for physician billing; not covered from facility or hospital	Yes

Importance

Infants at increased risk of severe RSV disease include premature infants, those with chronic lung or heart disease, and who have a weakened immune system. RSV can lead to severe infection like bronchiolitis and pneumonia. 2-3% of infants with RSV require hospitalization. Vaccinating pregnant people during the 3rd trimester or providing newborns an antibody injection can play an important role in avoiding severe disease and decreasing hospitalization.

Questions?

If you have any questions or concerns, please contact Health Partner Services at **1-855-607-2831**, Monday through Friday, 7:00 am CT/8:00 am ET to 7:00 pm CT/8:00 pm ET.

IN-MED-P-3245214; Issued Date: 02/10/2025

OMPP Approved: 02/06/2025